Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
NASDAQ:ONCE
Delisted

Spark Therapeutics Stock Price (Quote)

$113.57
+0 (+0%)
At Close: Jan 24, 2020

Range Low Price High Price Comment
30 days $113.57 $113.57 Friday, 24th Jan 2020 ONCE stock ended at $113.57. During the day the stock fluctuated 0% from a day low at $113.57 to a day high of $113.57.
90 days $108.00 $113.90
52 weeks $40.64 $114.20

Historical Spark Therapeutics prices

Date Open High Low Close Volume
Dec 17, 2019 $113.57 $113.57 $113.57 $113.57 23 897
Dec 16, 2019 $113.85 $113.90 $113.47 $113.57 2 517 195
Dec 13, 2019 $110.57 $111.30 $110.02 $110.75 770 383
Dec 12, 2019 $110.81 $111.24 $110.27 $110.55 681 446
Dec 11, 2019 $111.52 $112.00 $110.88 $110.91 430 829
Dec 10, 2019 $110.91 $112.14 $110.91 $111.90 469 833
Dec 09, 2019 $110.84 $111.64 $110.81 $111.14 411 583
Dec 06, 2019 $109.89 $110.74 $109.62 $110.65 322 473
Dec 05, 2019 $110.20 $110.50 $109.50 $109.68 364 310
Dec 04, 2019 $111.03 $111.03 $109.25 $109.99 1 219 769
Dec 03, 2019 $111.28 $111.60 $110.61 $110.89 404 009
Dec 02, 2019 $111.23 $111.52 $110.81 $111.30 306 520
Nov 29, 2019 $111.12 $111.54 $111.05 $111.14 90 248
Nov 27, 2019 $111.82 $111.82 $111.00 $111.16 323 233
Nov 26, 2019 $111.50 $111.61 $111.08 $111.49 241 924
Nov 25, 2019 $111.57 $111.75 $111.30 $111.42 300 753
Nov 22, 2019 $111.96 $111.96 $111.40 $111.45 282 929
Nov 21, 2019 $112.11 $112.19 $111.51 $111.55 389 669
Nov 20, 2019 $111.01 $112.24 $111.01 $112.00 543 656
Nov 19, 2019 $111.18 $112.50 $110.82 $111.33 286 777
Nov 18, 2019 $110.74 $111.94 $110.59 $111.15 397 303
Nov 15, 2019 $110.60 $111.03 $110.30 $110.81 283 444
Nov 14, 2019 $111.21 $111.35 $110.62 $110.81 293 750
Nov 13, 2019 $111.38 $111.79 $110.75 $111.37 443 424
Nov 12, 2019 $111.44 $111.94 $111.25 $111.57 449 164
Click to get the best stock tips daily for free!

About Spark Therapeutics

Spark Therapeutics Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company develops SPK-RPE65, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia... ONCE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT